Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.
What you feel with this company ? Are you willing to
Bristol-Myers Squibb Co.
Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
28,000 Employees Last Reported Date: 02/14/14
Founded in 1887
bristol-myers squibb co (BMY:New York)
As of 4:15 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).
bristol-myers squibb co (BMY) Snapshot
52 Week High
12/19/14 - $61.64
52 Week Low
06/5/14 - $46.30
Average Volume 10 Days
Request Investor Kit
BMY:US Advanced Stock Chart
bristol-myers squibb co (BMY) Related Bloomberg News
Lung Cancer Patients Say Don't Blame Us, Fund Us
12/09/2014 4:46 PM ET
Bristol-Myers, Merck Drugs Give Hope in Hodgkin’s Trials
12/07/2014 12:01 AM ET
Bayer, J&J Fight Calls to Unify Blood-Thinner Death Suits
12/04/2014 4:54 PM ET
Bristol-Myers Hepatitis C Drug Needs More Data on Combinations
11/26/2014 12:29 PM ET
'Mom Turned Into a Monster': 10,000 Seniors Go Missing in Japan
11/03/2014 8:17 PM ET
bristol-myers squibb co (BMY) Related
Prudential Piles on the Corporate Pensions
12/18/2014 4:50 PM ET
White-Collar Workers Live Longer and the Gap Is Widening
11/05/2014 1:15 PM ET
What's the Dollar Value of Online Patient Chatter?
10/09/2014 5:44 PM ET
It's Not Just Disruption: More Management Wisdom You Should Doubt
07/03/2014 5:49 AM ET
bristol-myers squibb co (BMY) Key Developments
Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announces Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors
Dec 10 14
Ono Pharmaceutical Co.,Ltd. Bristol-Myers Squibb Company and Kyowa Hakko Kirin Co., Ltd. announced the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody. The study, which will be conducted in Japan, will focus on evaluating the safety, tolerability and anti-tumor activity of combining Opdivo and mogamulizumab as a potential treatment option for patients with advanced or metastatic solid tumors. Opdivo, launched in Japan in September 2014 for the treatment of patients with unresectable melanoma, is being developed in multiple tumor types in more than 50 clinical trials worldwide. Mogamulizumab was launched in Japan in May 2012 for the treatment of relapsed or refractoryÂ CCR4-positive Adult T-cell Leukemia-Lymphoma (ATL), and granted the indication expansion in March 2014 for relapsed or refractory CCR4-positive Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). Clinical trials with mogamulizumab in ATL, PTCL, and CTCL are ongoing in the U.S., European Union (EU) and other countries. Opdivo and mogamulizumab are part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body's own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Opdivo binds to the checkpoint receptor PD-1 expressed on activated T-cells, blocking this pathway and enabling the immune system to attack tumors, while mogamulizumab can suppress some of the immune cells that shield the tumor from the immune system. Pre-clinical evidence for each therapy suggests the combination of Opdivo and mogamulizumab may lead to an enhanced anti-tumor immune response compared to either agent alone.
Bristol-Myers Squibb Company Declares Quarterly Dividend on Common Stock and Convertible Preferred Stock, Payable on February 2, 2015 and Payable on March 2, 2015 Respectively; Provides Dividend Guidance for the Full Year of 2015
Dec 9 14
The Board of Directors of Bristol-Myers Squibb Company declared a quarterly dividend of thirty-seven cents ($0.37) per share on the $0.10 par value common stock of the corporation. The next quarterly dividend will be payable on February 2, 2015, to stockholders of record at the close of business on January 2, 2015. The directors also declared a quarterly dividend of fifty cents ($0.50) per share on the $2.00 Convertible Preferred Stock of the corporation, payable March 2, 2015 to stockholders of record at the close of business on February 6, 2015. The directors indicated an expected dividend for the full year of 2015 of $1.48 per share on the $0.10 par value common stock of the corporation, subject to the normal quarterly review by the Board.
Bristol-Myers Jumps Amid Talk Of Potential Pfizer Bid
Dec 5 14
Shares of Bristol-Myers Squibb Company (NYSE:BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer Inc. (NYSE:PFE).
Market data is delayed at least 15 minutes.
Market data is delayed at least 15 minutes.
Biogen Idec Inc
Novo Nordisk A/S
Sponsored Financial Commentaries
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27
17 Dec 2014
[at noodls] - NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter and full year of 2014 on Tuesday, January 27, 2015. During a conference call at 9 a.m. EST ...
[at noodls] - NEW YORK--(BUSINESS WIRE)--The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-seven cents ($0.37) per share on the $.10 par value Common Stock ...
[at Financial Times] - Deutsche Bank and other firms are being pursued for more than $190m over allegedly setting up shell companies to avoid paying US taxes in 2000, according to a lawsuit filed Monday by the US attorney for ...
[at noodls] - Dateline: PRINCETON, N.J. & NEW YORK "The Bristol-Myers Squibb and Pfizer alliance remains committed to delivering important treatment options to patients and physicians and is pleased with the positive ...
Two Cancer Drugs for Hodgkin Lymphoma Shown Effective
8 Dec 2014
[at The Wall Street Journal] - Two cancer immunotherapy drugs being developed by Bristol-Myers and Merck proved remarkably effective against the blood cancer Hodgkin lymphoma in two small, separate studies, researchers said.
[Business Wire] - Bristol-Myers Squibb Company today announced positive results from a cohort of patients in its ongoing Phase 1b trial which evaluated PD-1 immune checkpoint inhibitor, Opdivo , in patients with relapsed or refractory hematological malignancies .